ALDER BIOPHARMACEUTICALS INC Contracts & Agreements

Second Supplemental Indenture, dated October 22, 2019, among Alder BioPharmaceuticals, Inc., Lundbeck LLC, and U.S. Bank National Association (Filed With SEC on October 22, 2019)

Letter Agreement, dated October 21, 2019, between Robert W. Azelby and Alder BioPharmaceuticals, Inc (Filed With SEC on October 22, 2019)

Alder BioPharmaceuticals, Inc. Executive Severance Benefit Plan, effective October 18, 2019 (Filed With SEC on October 22, 2019)

Agreement and Plan of Merger, dated September 16, 2019, by and among Alder BioPharmaceuticals, Inc., H. Lundbeck A/S, Lundbeck LLC and Violet Acquisition Corp (Filed With SEC on September 16, 2019)

2018 Inducement Award Plan, as Amended and Restated (Filed With SEC on August 6, 2019)

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement for the 2018 Inducement Award Plan (Filed With SEC on August 6, 2019)

Form of Stock Option Grant Notice and Option Agreement for the 2014 Equity Incentive Plan (for Annual Grants) (Filed With SEC on August 6, 2019)

Form of Stock Option Grant Notice and Option Agreement for the 2014 Equity Incentive Plan (for Initial Grants) (Filed With SEC on August 6, 2019)

Transition and Consulting Agreement between Alder BioPharmaceuticals, Inc. and John A. Latham, Ph.D. dated March 28, 2019 (Filed With SEC on May 2, 2019)

Compensation Information for Non-Employee Directors (Filed With SEC on May 2, 2019)

Registration Rights Agreement by and between Alder BioPharmaceuticals, Inc. and the buyers listed on the Schedule of Buyers thereto, dated March 4, 2019 (Filed With SEC on March 5, 2019)

Underwriting Agreement, dated February 27, 2019 (Filed With SEC on March 1, 2019)

Common Stock Purchase Agreement, dated February 26, 2019, by and between Alder BioPharmaceuticals, Inc., Redmile Group, LLC and certain institutional and other accredited... (Filed With SEC on March 1, 2019)

Transition Agreement between Alder BioPharmaceuticals, Inc. and Elisabeth A. Sandoval, dated November 2, 2018 (Filed With SEC on February 25, 2019)

Offer Letter between Alder BioPharmaceuticals, Inc. and Carlos E. Campoy dated December 4, 2018 (Filed With SEC on February 25, 2019)

Amendment to Offer Letter between Alder BioPharmaceuticals, Inc. and Carlos E. Campoy dated February 7, 2019. X 10.32+ Amended and Restated Executive Severance Benefit Plan (Filed With SEC on February 25, 2019)

Amendment No: 1 to the Contract Manufacturing Agreement between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective September 19, 2016 (Filed With SEC on February 25, 2019)

Amendment No: 2 to the Contract Manufacturing Agreement between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective November 17, 2016 (Filed With SEC on February 25, 2019)

Amendment No: 3.1 to the Contract Manufacturing Agreement between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective December 22, 2017 (Filed With SEC on February 25, 2019)

Amendment No: 4 to the Contract Manufacturing Agreement between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective June 15, 2018 (Filed With SEC on February 25, 2019)

Amendment No. 5 to the Contract Manufacturing Agreement between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective January 1, 2019 (Filed With SEC on February 25, 2019)

Contract Manufacturing Agreement between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective May 4, 2015 (Filed With SEC on February 25, 2019)

Quality Agreement on Manufacturing and Testing of Bulk Drug Substance between Alder BioPharmaceuticals, Inc. and Sandoz GmbH, effective July 27, 2018 (Filed With SEC on February 25, 2019)

Distribution Agreement, dated January 4, 2019, by and between Alder BioPharmaceuticals, Inc. and J.P. Morgan Securities LLC (Filed With SEC on January 4, 2019)

Amendment to Separation and Consulting Agreement with Randy Schatzman dated September 12, 2018 (Filed With SEC on November 5, 2018)

Offer Letter between the Company and Robert W. Azelby dated June 4, 2018 (Filed With SEC on August 7, 2018)

Form of Amendment to Stock Option Grant Notice and Option Agreement for the 2014 Equity Incentive Plan (Filed With SEC on August 7, 2018)

Form of Stock Option Grant Notice and Option Agreement for the 2014 Equity Incentive Plan (For awards after June 14, 2018) (Filed With SEC on August 7, 2018)

Form of Restricted Stock Unit Award Grant Notice and Option Agreement (Time-Based Vesting) for the 2014 Equity Incentive Plan (Filed With SEC on August 7, 2018)

Form of Restricted Stock Unit Award Grant Notice and Option Agreement (Performance-Based Vesting) for the 2014 Equity Incentive Plan (Filed With SEC on August 7, 2018)

2018 Inducement Award Plan (Filed With SEC on August 7, 2018)

Form of Stock Option Grant Notice and Option Agreement (Time-Based Vesting) for the 2018 Inducement Award Plan (Filed With SEC on August 7, 2018)

Form of Stock Option Grant Notice and Option Agreement (Performance-Based Vesting) for the 2018 Inducement Award Plan (Filed With SEC on August 7, 2018)

Settlement and License Agreement, by and between the Company, AlderBio Holdings, LLC and Teva Pharmaceuticals International GmbH, dated January 5, 2018 (Filed With SEC on May 8, 2018)

Separation and Consulting Agreement between the Company and Randall C. Schatzman dated March 26, 2018 (Filed With SEC on May 8, 2018)

Offer Letter between the Company and Paul B. Cleveland dated March 18, 2018 (Filed With SEC on May 8, 2018)

Offer Letter between the Company and Erin Lavelle dated March 17, 2018 (Filed With SEC on May 8, 2018)

Separation and Consulting Agreement between Alder BioPharmaceuticals, Inc. and Timothy M. Whitaker, M.D., dated June 3, 2016 (Filed With SEC on February 26, 2018)

Amendment to Offer Letter between Alder BioPharmaceuticals, Inc., and Elisabeth A. Sandoval, dated January 2, 2018 (Filed With SEC on February 26, 2018)

Underwriting Agreement, dated January 29, 2018 (Filed With SEC on February 1, 2018)

Base Indenture, dated February 1, 2018, between the Company and U.S. Bank National Association, as Trustee (Filed With SEC on February 1, 2018)

First Supplemental Indenture, dated February 1, 2018, between the Company and U.S. Bank National Association, as Trustee (including the form of 2.50% convertible senior notes due... (Filed With SEC on February 1, 2018)

Registration Rights Agreement by and between Alder BioPharmaceuticals, Inc. and the buyers listed on the Schedule of Buyers thereto, dated January 12, 2018 (Filed With SEC on January 19, 2018)

Preferred Stock Purchase Agreement by and among Alder BioPharmaceuticals, Inc. and the Buyers set forth therein dated January 7, 2018 (Filed With SEC on January 11, 2018)

Underwriting Agreement, dated July 12, 2017 (Filed With SEC on July 14, 2017)

Alder BioPharmaceuticals, Inc. Executive Severance Benefit Plan (Filed With SEC on February 23, 2017)

FIFTH AMENDMENT TO LEASE (Filed With SEC on November 21, 2016)

ALDER BIOPHARMACEUTICALS, INC. 5,376,344 Shares of Common Stock Underwriting Agreement (Filed With SEC on April 8, 2016)

FOURTH AMENDMENT TO LEASE (Filed With SEC on February 23, 2016)

4,494,382 Shares ALDERBIOPHARMACEUTICALS, INC. COMMON STOCK UNDERWRITING AGREEMENT (Filed With SEC on June 26, 2015)

[ ] Shares ALDER BIOPHARMACEUTICALS, INC. COMMON STOCK UNDERWRITING AGREEMENT (Filed With SEC on December 22, 2014)

Additional abbreviations mayalso be used though not in the above list. (Filed With SEC on December 22, 2014)

ALDER BIOPHARMACEUTICALS, INC. 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MARCH 31, 2014 APPROVED BY THE STOCKHOLDERS:APRIL 7, 2014 (Filed With SEC on May 1, 2014)

COLLABORATION AND LICENSE AGREEMENT Among ALDERBIOHOLDINGS LLC, ALDER BIOPHARMACEUTICALS INC. and BRISTOL-MYERSSQUIBB COMPANY (Filed With SEC on May 1, 2014)

ADDENDUM NO. 1 TOCOLLABORATION AND LICENSE AGREEMENT (Filed With SEC on May 1, 2014)

MASTER SERVICES AGREEMENT (Filed With SEC on May 1, 2014)

EXHIBIT B LICENSEAGREEMENT (Filed With SEC on May 1, 2014)

Master Product Development and Clinical Supply Agreement (Filed With SEC on May 1, 2014)

FIRST AMENDMENT TO MASTER PRODUCT DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on May 1, 2014)

[ ] ALDER BIOPHARMACEUTICALS, INC. COMMON STOCK UNDERWRITING AGREEMENT (Filed With SEC on April 25, 2014)

ALDER BIOPHARMACEUTICALS, INC. AMENDMENT NO. 1 TO AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT (Filed With SEC on April 25, 2014)

INDEMNITY AGREEMENT (Filed With SEC on April 25, 2014)

ALDER BIOPHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MARCH 31, 2014 APPROVED BY THE STOCKHOLDERS:APRIL 7, 2014 IPO DATE/EFFECTIVE DATE: ,... (Filed With SEC on April 25, 2014)

ALDER BIOPHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE (2014 EQUITY INCENTIVE PLAN) (Filed With SEC on April 25, 2014)

ALDER BIOPHARMACEUTICALS, INC. EXECUTIVE SEVERANCE BENEFIT PLAN (Filed With SEC on April 25, 2014)

Master Product Development and Clinical Supply Agreement (Filed With SEC on April 25, 2014)

FIRST AMENDMENT TO MASTER PRODUCT DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (Filed With SEC on April 25, 2014)

ALDER BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT April 16, 2012 TABLE OF CONTENTS (Filed With SEC on March 19, 2014)

ALDER BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED 2005 STOCK PLAN (Filed With SEC on March 19, 2014)

ALDER BIOPHARMACEUTICALS, INC. 2005 STOCK PLAN NOTICE OF STOCK OPTION GRANT (Filed With SEC on March 19, 2014)

ALDER BIOPHARMACEUTICALS, INC. EXECUTIVE CHANGE IN CONTROL SEVERANCE BENEFITPLAN (Filed With SEC on March 19, 2014)

COLLABORATION AND LICENSE AGREEMENT Among ALDERBIOHOLDINGS LLC, ALDER BIOPHARMACEUTICALS INC. and BRISTOL-MYERSSQUIBB COMPANY (Filed With SEC on March 19, 2014)

ADDENDUM NO. 1 TOCOLLABORATION AND LICENSE AGREEMENT (Filed With SEC on March 19, 2014)

MASTER SERVICES AGREEMENT (Filed With SEC on March 19, 2014)

EXHIBIT B LICENSEAGREEMENT (Filed With SEC on March 19, 2014)

EARLY ENTRY AGREEMENT (Filed With SEC on March 19, 2014)

FIRST AMENDMENT TO LEASE (Filed With SEC on March 19, 2014)

SECOND AMENDMENT TO LEASE (Filed With SEC on March 19, 2014)

THIRD AMENDMENT TO LEASE (Filed With SEC on March 19, 2014)

Alder BioPharmaceuticals July 19, 2005 (Filed With SEC on March 19, 2014)

Category

Industry

Companies

Contracts

ALDER BIOPHARMACEUTICALS INC Contracts & Agreements